Literature DB >> 3002067

Production and characterization of monoclonal antibodies directed against pseudorabies virus.

L M Wathen, K B Platt, M W Wathen, R A Van Deusen, C A Whetstone, E C Pirtle.   

Abstract

Hybridoma cell lines producing monoclonal antibodies to pseudorabies virus (PRV) were established. The monoclonal antibodies were characterized with respect to their antigenic specifications and biological activities. Two monoclonal antibodies immunoprecipitated the 50 kDa PRV glycoprotein (gp50) and two immunoprecipitated the 82 kDa glycoprotein (gp82). The monoclonal antibodies were used to analyze the biological roles of these two glycoproteins. One monoclonal antibody directed against each glycoprotein did not require complement for in vitro viral neutralization while the other monoclonal antibody directed against the glycoprotein required complement for neutralization. The monoclonal antibodies against gp50 were shown to be directed against different epitopes within the glycoprotein. In contrast, the monoclonal antibodies against gp82 were shown to be directed against the same antigenic site on the glycoprotein. In vivo passive immunity studies in mice showed that monoclonal antibodies directed against either gp50 or gp82 could be protective.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3002067     DOI: 10.1016/0168-1702(85)90017-6

Source DB:  PubMed          Journal:  Virus Res        ISSN: 0168-1702            Impact factor:   3.303


  11 in total

1.  Correlation between gI, gII, gIII, and gp 50 antibodies and virus excretion in vaccinated pigs infected with pseudorabies virus.

Authors:  M Eloit; P Vannier; E Hutet; A Fournier
Journal:  Arch Virol       Date:  1992       Impact factor: 2.574

2.  Evaluation of pseudorabies virus glycoprotein gp50 as a vaccine for Aujeszky's disease in mice and swine: expression by vaccinia virus and Chinese hamster ovary cells.

Authors:  C C Marchioli; R J Yancey; E A Petrovskis; J G Timmins; L E Post
Journal:  J Virol       Date:  1987-12       Impact factor: 5.103

3.  Production of a baculovirus-derived gp50 protein and utilization in a competitive enzyme-linked immunosorbent assay for the serodiagnosis of pseudorabies virus.

Authors:  I Prud'homme; E M Zhou; M Traykova; H Trotter; M Chan; A Afshar; M J Harding
Journal:  Can J Vet Res       Date:  1997-10       Impact factor: 1.310

4.  Use of Staby(®) technology for development and production of DNA vaccines free of antibiotic resistance gene.

Authors:  Anca Reschner; Sophie Scohy; Gaëlle Vandermeulen; Marc Daukandt; Céline Jacques; Benjamin Michel; Hans Nauwynck; Florence Xhonneux; Véronique Préat; Alain Vanderplasschen; Cédric Szpirer
Journal:  Hum Vaccin Immunother       Date:  2013-06-04       Impact factor: 3.452

5.  Vaccine-induced, pseudorabies virus-specific, extrathymic CD4+CD8+ memory T-helper cells in swine.

Authors:  B T Ober; A Summerfield; C Mattlinger; K H Wiesmüller; G Jung; E Pfaff; A Saalmüller; H J Rziha
Journal:  J Virol       Date:  1998-06       Impact factor: 5.103

6.  Mapping and characterization of neutralizing epitopes of glycoproteins gIII and gp50 of the Indiana-Funkhauser strain of pseudorabies virus.

Authors:  N E Coe; W L Mengeling
Journal:  Arch Virol       Date:  1990       Impact factor: 2.574

7.  Characterization and mapping of a nonessential pseudorabies virus glycoprotein.

Authors:  M W Wathen; L M Wathen
Journal:  J Virol       Date:  1986-04       Impact factor: 5.103

8.  DNA sequence of the gene for pseudorabies virus gp50, a glycoprotein without N-linked glycosylation.

Authors:  E A Petrovskis; J G Timmins; M A Armentrout; C C Marchioli; R J Yancey; L E Post
Journal:  J Virol       Date:  1986-08       Impact factor: 5.103

9.  Pseudorabies virus glycoprotein gIII is a major target antigen for murine and swine virus-specific cytotoxic T lymphocytes.

Authors:  F A Zuckermann; L Zsak; T C Mettenleiter; T Ben-Porat
Journal:  J Virol       Date:  1990-02       Impact factor: 5.103

10.  Identification of the pseudorabies virus glycoprotein gp50 as a major target of neutralizing antibodies.

Authors:  M Eloit; D Fargeaud; R L'Haridon; B Toma
Journal:  Arch Virol       Date:  1988       Impact factor: 2.574

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.